Please assess the completion status of the following clinical trial:

Trial Title: Time To Complications Occurs in Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diabetes type 1, 2 or LADA: 18-75 years of age.~* Group A: 150 Type 1 Diabetes, duration 15 years (+/-2 years) and 150 Type 2~* Diabetes 2 years (+/-2 years) (50% F/M)~* Group B: 150 Type 1 Diabetes, duration 20 years (+/-2 years) and 150 Type 2~* Diabetes 7 years (+/-2 years) (50% F/M)~* Group C: 150 Type 1 Diabetes, duration 25 years (+/-2 years) and 150 Type 2~* Diabetes 12 years (+/-2 years) (50% F/M)~* Group D: 50 LADA, onset after 35 years of age, duration of 5-10 years (50% F/M)~* Type 1 Diabetes: Positive ICA antibodies and/or GAD-antibodies and/or neg C-peptide. Debut \<30 years of age.~* Type 2 Diabetes: Negative ICA-antibodies and GAD-antibodies and pos C-peptide (\>0.35 mmol/l).~* LADA: Positive ICA-antibodies and/or GAD-antibodies. Debut \>35 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: None): 150 Type 1 Diabetes, duration of 15 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 2 years (+/- 2 years) (50% women / men)
- Group B (Type: None): 150 Type 1 Diabetes, duration of 20 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 7 years (+/- 2 years) (50% women / men)
- Group C (Type: None): 150 Type 1 Diabetes, duration of 25 years (+/- 2 years) and 150 Type 2 Diabetes duration of 12 years (+/- 2 years) (50% women / men)
- Group D (Type: None): 50 LADA (Late Autoimmune Diabetes in Adults), debut after 35 years of age, duration of 5-10 years (50% women / men)

Based on this trial design, predict the completion outcome and termination type (if applicable).